Safety, Reactogenicity, and Immunogenicity of a Recombinant Protective Antigen Anthrax Vaccine Given to Healthy Adults
Human Vaccines2007Vol. 3(5), pp. 205–211
Citations Over TimeTop 12% of 2007 papers
James D. Campbell, Kristin H. Clement, Steven A. Wasserman, Sarah Donegan, Lisa Chrisley, Karen L. Kotloff
Abstract
This recombinant Protective Antigen anthrax vaccine, when given with the adjuvant Alhydrogel to healthy adults in two intramuscular injections four weeks apart, is very well-tolerated and highly immunogenic.
Related Papers
- → The early humoral immune response toBacillus anthracistoxins in patients infected with cutaneous anthrax(2011)29 cited
- → Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes(2020)13 cited
- → Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R(2016)14 cited
- → Study of Immunization against Anthrax with the Purified Recombinant Protective Antigen of Bacillus anthracis(1998)46 cited
- Progress in research on neutralizing antibody against Bacillus anthracis(2010)